April 21, 2010 - Breakthrough Approach to Treating Metabolic and Inflammatory Conditions – Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures. Proceeds from the financing will be used to advance Catabasis’ lead program targeting type 2 diabetes, and to further the development of the company’s proprietary platform technology in additional inflammatory and metabolic diseases... [PDF] Catabasis Pharmaceuticals' Press Release -
Tuesday, April 27, 2010
Catabasis Pharmaceuticals : $39.6 Million Series A Funding
April 21, 2010 - Breakthrough Approach to Treating Metabolic and Inflammatory Conditions – Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures. Proceeds from the financing will be used to advance Catabasis’ lead program targeting type 2 diabetes, and to further the development of the company’s proprietary platform technology in additional inflammatory and metabolic diseases... [PDF] Catabasis Pharmaceuticals' Press Release -
